Validity of cognitive screens for HIV-associated neurocognitive disorder: A systematic review and an informed screen selection guide

Current HIV/AIDS Reports

Volumn 10, Issue 4, 2013, Pages 342-355

  Kamminga, Jody ^a,b   Cysique, Lucette A ^a,b,d   Lu, Grace ^a,d   Batchelor, Jennifer ^c   Brew, Bruce J ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

AIDS; Cognitive screen; Computerised screen; Construct validity; Criterion validity; HAND; HIV; HIV dementia scale; Neuropsychology; Systematic review

Indexed keywords

ANTIRETROVIRUS AGENT;

CONSTRUCT VALIDITY; CRITERION RELATED VALIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GOLD STANDARD; HAND SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

COGNITION DISORDERS; HIV INFECTIONS; HUMANS; MASS SCREENING; NEUROPSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84891125183     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0176-6     Document Type: Review

References (46)

1. UNAIDS: UNAIDS report on the global AIDS epidemic, 2012. Available at http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/ gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf.
2. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10:350-7.
3. Heaton RK, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231-51.
4. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915-21.
5. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res and Hum Retroviruses. 2005;21:706-13.
6. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25(Mothobi NZ, Brew BJ):4-9. Summarises the most likely cause of HIV brain impairment in cART era.
7. Heaton RK, Clifford DB, Franklin Jr DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-96. Characteristation of HAND in the cART era, with mild HAND being the prominent form of HAND today.
8. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. Neurology. 1996, 47:1247-53.
9. [No authors listed]. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology. 1991, 41:778-85.
10. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-99.
11. Cysique LA, Bain MP, Lane TA, Brew BJ. Management issues in HIV-associated neurocognitive disorders. Neurobehav HIV Med. 2012;4:63-73. Current review on HIV/AIDS management from a clinical neuropsycholoigcal perspective.
12. Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25:561-75. Up to date review of neurological management of HIV/AIDS.
13. Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol. 2001;58:473-9.
14. Heaton RK, Franklin D, Woods S, et al.: Asymptomatic mild HIV-associated neurocognitive disorder increases risk for future symptomatic decline: A CHARTER longitudinal study. Presented at the conference on retroviruses and opportunistic infections. Seattle, United States of America March, 2012.
15. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:273-8.
16. Cysique LA, Letendre SL, Ake C, et al. Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS. 2010;24:983-90. Describes the initial algorithmic use of a cognitive screening strategy.
17. Valcour V, Paul R, Chiao S, et al. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53:836-42. Existing literature review of current HAND screens. Note, this does not include all available studies, and did not differentiate between pre and post cART era or between those who used neuropsychological assesment as the gold standard.
18. Haddow LJ, Floyd S, Copas A, Gilson RJ. A systematic review of the screening accuracy of the HIV dementia scale and international HIV dementia scale. PLoS One. 2013;8:e61826. Comprehensive review of existing HIV Dementia Scale and International HIV Dementia Scale.
19. Overton ET, Kauwe JS, Paul R, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15:1902-9.
20. Sakamoto M, Marcotte TD, Umlauf A, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr Hum Retrovirol. 2013;62:36-42.
21. Becker JT, Dew MA, Aizenstein HJ, et al. Concurrent validity of a computer-based cognitive screening tool for use in adults with HIV disease. AIDS Patient Care STDS. 2011;25:351-7.
22. Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10:246-52.
23. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234-48.
24. Levine AJ, Palomo M, Hinkin CH, et al. A comparison of screening batteries in the detection of neurocognitive impairment in HIV-infected Spanish speakers. Neurobehav HIV Med. 2011;2011:79-86.
25. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21:185-94.
26. Saxton J, Morrow L, Eschman A, et al. Computer assessment of mild cognitive impairment. Postgrad Med. 2009;121:177-85.
27. Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc. 2003;9:64-71.
28. Miller EN. California computerised assessment battery (CalCAP) manual. Los Angeles: Norland Software; 1990.
29. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367-74.
30. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the NeuroScreen. J Neurovirol. 2005;11:503-11.
31. Moore DJ, Roediger MJ, Eberly LE, et al. Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-Infected Cohort. PLoS One. 2012;7:e47310.
32. Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci. 2007;260:11-5.
33. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-50.
34. Joska JA, Westgarth-Taylor J, Hoare J, et al. Validity of the international HIV dementia scale in South Africa. AIDS Patient Care STDS. 2011;25:95-101.
35. Singh D, Sunpath H, John S, Eastham J, Gouden R. The utility of a rapid screening tool for depression and HIV dementia amongst patients with low CD4 counts - a preliminary report. African J Psychiatry. 2008;11:282-6.
36. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158:1079-83.
37. Wonja V, Skolasky RL, McArthur JC, et al. Spanish validation of the HIV dementia scale in women. AIDS Patient Care STDS. 2007;21:930-41.
38. Chalermchai T, Sithinamsuwam P, Clifford D, et al. Trail Making Test A improve performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol. 2013;19:137-43.
39. Smith CA, van Gorp WG, Ryan ER, et al. Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr Hum Retrovirol. 2003;33:116-8.
40. Morgan EE, Woods SP, Scott JC, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2008;30:83-90.
41. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-Associated Neurocognitive Disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56:1004-17.
42. Cherner M, Cysique L, Heaton RK, et al. Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol. 2007;13:23-8.
43. Elwood R. Psychological tests and clinical discriminations: beginning to adress the base rate problem. Clinical Psychol Rev. 1993;13:409-19.
44. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447-50.
45. Richardson MA, Morgan EE, Vielhauer MJ, et al. Utility of the HIV dementia scale in assessing risk for significant HIV-related cognitive-motor deficits in a high-risk urban adult sample. AIDS Care. 2005;17:1013-21.
46. Cysique L, Deutsch R, Atkinson J, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc. 2007;13:1-11.